{"id":"rifampin-isoniazid-fdc","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"0.2-2","effect":"Peripheral neuropathy"},{"rate":"3-5","effect":"Gastrointestinal disturbance"},{"rate":"1-2","effect":"Rash"},{"rate":"0.1-1","effect":"Drug-induced lupus-like syndrome"}]},"_chembl":{"chemblId":"CHEMBL64","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampin inhibits bacterial RNA polymerase, blocking transcription and RNA synthesis in mycobacteria. Isoniazid is a prodrug that is activated by mycobacterial catalase-peroxidase and inhibits mycolic acid synthesis, which is essential for the mycobacterial cell wall. Together, they provide synergistic bactericidal activity against tuberculosis.","oneSentence":"Rifampin and isoniazid are bactericidal antibiotics that inhibit bacterial RNA polymerase and mycolic acid synthesis, respectively, to kill Mycobacterium tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:02.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"},{"name":"Latent tuberculosis infection (as part of combination therapy)"}]},"trialDetails":[{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT04260477","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimen","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-03-01","conditions":"Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":370},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT05005637","phase":"PHASE2","title":"The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2021-08-27","conditions":"Tuberculous Uveitis","enrollment":78},{"nctId":"NCT03800381","phase":"","title":"Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-28","conditions":"Tuberculosis, Human Immunodeficiency Virus, Coinfection","enrollment":92},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT04088019","phase":"","title":"Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-10-30","conditions":"Tuberculosis; Uveitis (Manifestation), Anti-Tuberculous Drug Reaction, Tuberculous Uveitis","enrollment":50},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT02457208","phase":"PHASE1","title":"PK Study of Anti-TB Drugs","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-07-07","conditions":"Tuberculosis","enrollment":61},{"nctId":"NCT02953847","phase":"PHASE1","title":"The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2016-11","conditions":"Tuberculosis","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rifampin/isoniazid FDC","genericName":"Rifampin/isoniazid FDC","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampin and isoniazid are bactericidal antibiotics that inhibit bacterial RNA polymerase and mycolic acid synthesis, respectively, to kill Mycobacterium tuberculosis. Used for Tuberculosis (pulmonary and extrapulmonary), Latent tuberculosis infection (as part of combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}